Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.
V. Stearns
Honoraria - AstraZeneca
Research Funding - Abraxis BioScience; Merck; Novartis; Pfizer
J. W. Chapman
No relevant relationships to disclose
C. X. Ma
No relevant relationships to disclose
M. J. Ellis
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Research Funding - AstraZeneca; Novartis
Other Remuneration - AstraZeneca; Novartis; Pfizer
J. N. Ingle
Other Remuneration - Pfizer
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience; Amgen; Boehringer Ingelheim; Novartis; Pfizer; Roche
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Expert Testimony - AstraZeneca; Novartis
G. T. Budd
Consultant or Advisory Role - AstraZeneca; Pfizer
M. Rabaglio
No relevant relationships to disclose
G. W. Sledge
No relevant relationships to disclose
A. Le Maitre
No relevant relationships to disclose
J. Kundapur
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer